CliffBio
biologic

Emrelis

telisotuzumab vedotin-tllv

Loss of exclusivityMay 2037projected — 12-year biologic exclusivity estimate
CompanyAbbVie Inc. →View the full company profile on CliffBio

Drug detail

Brand nameEmrelis
Active ingredienttelisotuzumab vedotin-tllv
Strength100MG
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalMay 2025
Marketing statusRx

More from AbbVie Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Emrelis patent cliff — loss of exclusivity May 2037 | CliffBio